• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Neoadjuvant therapy affects tumor growth markers in early stage non-small-cell lung cancer.新辅助治疗影响早期非小细胞肺癌的肿瘤生长标志物。
Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):42-4. doi: 10.1186/2047-783x-14-s4-42.
2
Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.对于ⅢA期（N2）非小细胞肺癌患者，在手术切除前接受新辅助化疗和/或放疗是否有生存获益：一项系统评价和Meta分析
Medicine (Baltimore). 2015 Jun;94(23):e879. doi: 10.1097/MD.0000000000000879.
3
[Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].[通过多基因表达预测新辅助化疗对可切除的IIIA期非小细胞肺癌的疗效]
Ai Zheng. 2005 Jul;24(7):846-9.
4
Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.早期非小细胞肺癌：综合治疗的当前观点
Clin Lung Cancer. 2004 Sep;6(2):85-98. doi: 10.3816/CLC.2004.n.022.
5
Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands.荷兰局部晚期非小细胞肺癌新辅助化疗（放疗）和切除术的结果。
Acta Oncol. 2020 Jul;59(7):748-752. doi: 10.1080/0284186X.2020.1757150. Epub 2020 Apr 29.
6
[Efficacy and Potential Application of Neoadjuvant Chemotherapy in Patients with IIIa Stage Non-small Cell Lung Cancer].新辅助化疗在Ⅲa期非小细胞肺癌患者中的疗效及潜在应用
Zhongguo Fei Ai Za Zhi. 2017 Feb 20;20(2):100-106. doi: 10.3779/j.issn.1009-3419.2017.02.04.
7
Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).血管内皮生长因子（VEGF）和血管内皮生长因子受体 1（FLT1）表达对接受放疗的 II/III 期非小细胞肺癌（NSCLC）患者预后的影响。
Strahlenther Onkol. 2010 Jun;186(6):307-14. doi: 10.1007/s00066-010-2131-4. Epub 2010 Apr 26.
8
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
9
Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.在 III 期非小细胞肺癌患者新辅助化疗治疗中，血清 p53 抗体、癌胚抗原和糖类抗原 12-5 的检测及其预测价值。
Clin Chim Acta. 2011 May 12;412(11-12):930-5. doi: 10.1016/j.cca.2011.01.028. Epub 2011 Jan 28.
10
Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.早期非小细胞肺癌的辅助治疗和新辅助治疗。
Clin Lung Cancer. 2005 Dec;7 Suppl 3:S98-104. doi: 10.3816/clc.2005.s.018.

本文引用的文献

1
[Effect of cisplatin on expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and their correlations in Lewis lung cancer in mice].[顺铂对小鼠Lewis肺癌中基质金属蛋白酶-9和金属蛋白酶组织抑制剂-1表达的影响及其相关性]
Ai Zheng. 2009 Jul;28(7):685-90. doi: 10.5732/cjc.009.10025.
2
Doxorubicin inhibits TGF-beta signaling in human lung carcinoma A549 cells.阿霉素抑制人肺癌A549细胞中的转化生长因子-β信号传导。
Eur J Pharmacol. 2008 Aug 20;590(1-3):67-73. doi: 10.1016/j.ejphar.2008.05.030. Epub 2008 May 29.
3
Multimodality approach to early-stage non-small cell lung cancer.早期非小细胞肺癌的多模态治疗方法
Lung Cancer. 2007 Aug;57 Suppl 2:S6-11. doi: 10.1016/S0169-5002(07)70421-X.
4
Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy.非小细胞肺癌：辅助化疗和新辅助化疗
Respirology. 2007 May;12(3):320-5. doi: 10.1111/j.1440-1843.2007.01081.x.
5
Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.血管内皮生长因子、p53、Rb、Bcl-2表达与晚期非小细胞肺癌化疗反应
Lung Cancer. 2004 Oct;46(1):77-85. doi: 10.1016/j.lungcan.2004.03.018.
6
Potential role of transforming growth factor beta1 in drug resistance of tumor cells.转化生长因子β1在肿瘤细胞耐药中的潜在作用。
Acta Biochim Pol. 2003;50(2):497-508.
7
Malignant cells, directors of the malignant process: role of transforming growth factor-beta.恶性细胞，恶性过程的主导者：转化生长因子-β的作用
Cancer Metastasis Rev. 2001;20(1-2):133-43. doi: 10.1023/a:1013177011767.
8
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.在可切除的Ⅰ期（T1N0除外）、Ⅱ期和Ⅲa期非小细胞肺癌中，术前化疗后手术与直接手术的比较。
J Clin Oncol. 2002 Jan 1;20(1):247-53. doi: 10.1200/JCO.2002.20.1.247.
9
Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance.Fas（CD95/APO-1）及Fas配体在肺癌中的表达及其预后和预测相关性。
Int J Cancer. 1999 Jun 21;84(3):239-43. doi: 10.1002/(sici)1097-0215(19990621)84:3<239::aid-ijc7>3.0.co;2-s.
10
Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line.转化生长因子-β1增强DNA损伤剂对人肺癌细胞系的致死作用。
Int J Cancer. 1997 Jul 17;72(2):356-61. doi: 10.1002/(sici)1097-0215(19970717)72:2<356::aid-ijc26>3.0.co;2-c.

新辅助治疗影响早期非小细胞肺癌的肿瘤生长标志物。

Neoadjuvant therapy affects tumor growth markers in early stage non-small-cell lung cancer.

机构信息

Laboratory of Molecular Diagnostics and Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.

出版信息

Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):42-4. doi: 10.1186/2047-783x-14-s4-42.

DOI:10.1186/2047-783x-14-s4-42
PMID:20156723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3521347/
Abstract

INTRODUCTION

While adjuvant therapy of early-stage non-small-cell lung cancer (NSCLC) is widely accepted, literature data concerning neoadjuvant treatment provide contradictory results with both improved and unaffected survival rates. Also, data concerning potential effects of neo-adjuvant therapy on cellular level are scarce.

OBJECTIVE

The aim of present study was to analyze the effect of chemotherapy followed by surgical resection on several key biological markers of tumor growth (TGF-beta, VEGF), apoptosis (sAPO-1/Fas/CD95) and invasiveness (TIMP-1) assessed in the sera of NSCLC early-stage patients (IB-IIIA). -

MATERIAL AND METHODS

Measurements were performed by ELISA method in blood serum from 24 NSCLC patients (I-IIIA) collected prior therapy, one day before surgery and 3 days after.

RESULTS

TGF-beta serum concentrations were significantly lower after both chemotherapy (P<0.05) and surgery (P<0.01) in comparison to the baseline. VEGF levels decreased following NEO therapy with subsequent significant up-regulation after surgery (P<0.001). Interestingly, post-surgery serum VEGF strongly correlated with TGF-beta concentration (r = 0.52, P = 0.014). No significant differences were observed for serum sAPO-1/CD95/FAS as well as TIMP-1 concentrations at any of three evaluated time-points.

CONCLUSION

Neoadjuvant treatment of early-stage NSCLC affects mostly mechanisms responsible for tumor growth and vascularization. Its effect on cancer cells apoptotic activity needs further evaluation.

摘要

简介

虽然辅助治疗早期非小细胞肺癌（NSCLC）已被广泛接受，但有关新辅助治疗的文献数据提供了相互矛盾的结果，既有改善的生存率，也有未受影响的生存率。此外，关于新辅助治疗对细胞水平潜在影响的数据也很少。

目的

本研究旨在分析化疗后手术切除对早期非小细胞肺癌（IB-IIIA）患者血清中几种肿瘤生长关键生物学标志物（TGF-β、VEGF）、凋亡（sAPO-1/Fas/CD95）和侵袭性（TIMP-1）的影响。

材料和方法

通过 ELISA 法在 24 名 NSCLC 患者（I-IIIA）的血清中进行测量，这些患者在治疗前、手术前一天和手术后 3 天采集血液。

结果

与基线相比，化疗（P<0.05）和手术（P<0.01）后血清 TGF-β浓度均显著降低。NEO 治疗后 VEGF 水平下降，随后手术后显著上调（P<0.001）。有趣的是，手术后血清 VEGF 与 TGF-β浓度强烈相关（r = 0.52，P = 0.014）。在三个评估时间点中的任何一个时间点，血清 sAPO-1/CD95/FAS 以及 TIMP-1 浓度均无显著差异。

结论

早期 NSCLC 的新辅助治疗主要影响肿瘤生长和血管生成的机制。其对癌细胞凋亡活性的影响需要进一步评估。